A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was found to be 77.8 percent effective at preventing symptomatic COVID-19 in a large Phase 3 clinical trial.
Category: Health & Wellbeing, Lifestyle
Tags: Coronavirus (COVID-19), Vaccines, Virus, India
PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.
